The SCAP/SREBP pathway: A mediator of hepatic steatosis

Young Ah Moon

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance, obesity, and dyslipidemia. NAFLD encompasses a wide range of states from the simple accumulation of triglycerides in the hepatocytes to serious states accompanied by inflammation and fibrosis in the liver. De novo lipogenesis has been shown to be a significant factor in the development of hepatic steatosis in insulin-resistant states. Sterol regulatory element binding protein-1c (SREBP-1c) is the main transcription factor that mediates the activation of lipogenesis, and SREBP cleavage activating protein (SCAP) is required for the activation of SREBPs. Here, recent animal studies that suggest SCAP as a therapeutic target for hepatic steatosis and hypertriglyceridemia are discussed.

Original languageEnglish (US)
Pages (from-to)6-10
Number of pages5
JournalEndocrinology and Metabolism
Volume32
Issue number1
DOIs
StatePublished - Mar 1 2017

Fingerprint

Lipogenesis
Sterol Regulatory Element Binding Protein 1
Hypertriglyceridemia
Liver
Dyslipidemias
Liver Cirrhosis
Insulin Resistance
Hepatocytes
Triglycerides
Transcription Factors
Obesity
Insulin
Inflammation
SREBP cleavage-activating protein
Non-alcoholic Fatty Liver Disease
Therapeutics

Keywords

  • Hypertriglyceridemia
  • Insulin resistance
  • Lipogenesis
  • Non-alcoholic fatty liver disease

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

The SCAP/SREBP pathway : A mediator of hepatic steatosis. / Moon, Young Ah.

In: Endocrinology and Metabolism, Vol. 32, No. 1, 01.03.2017, p. 6-10.

Research output: Contribution to journalReview article

Moon, Young Ah. / The SCAP/SREBP pathway : A mediator of hepatic steatosis. In: Endocrinology and Metabolism. 2017 ; Vol. 32, No. 1. pp. 6-10.
@article{9192a5c2842b44ef8916384640334503,
title = "The SCAP/SREBP pathway: A mediator of hepatic steatosis",
abstract = "Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance, obesity, and dyslipidemia. NAFLD encompasses a wide range of states from the simple accumulation of triglycerides in the hepatocytes to serious states accompanied by inflammation and fibrosis in the liver. De novo lipogenesis has been shown to be a significant factor in the development of hepatic steatosis in insulin-resistant states. Sterol regulatory element binding protein-1c (SREBP-1c) is the main transcription factor that mediates the activation of lipogenesis, and SREBP cleavage activating protein (SCAP) is required for the activation of SREBPs. Here, recent animal studies that suggest SCAP as a therapeutic target for hepatic steatosis and hypertriglyceridemia are discussed.",
keywords = "Hypertriglyceridemia, Insulin resistance, Lipogenesis, Non-alcoholic fatty liver disease",
author = "Moon, {Young Ah}",
year = "2017",
month = "3",
day = "1",
doi = "10.3803/EnM.2017.32.1.6",
language = "English (US)",
volume = "32",
pages = "6--10",
journal = "Endocrinology and Metabolism",
issn = "2093-596X",
publisher = "Korean Endocrine Society",
number = "1",

}

TY - JOUR

T1 - The SCAP/SREBP pathway

T2 - A mediator of hepatic steatosis

AU - Moon, Young Ah

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance, obesity, and dyslipidemia. NAFLD encompasses a wide range of states from the simple accumulation of triglycerides in the hepatocytes to serious states accompanied by inflammation and fibrosis in the liver. De novo lipogenesis has been shown to be a significant factor in the development of hepatic steatosis in insulin-resistant states. Sterol regulatory element binding protein-1c (SREBP-1c) is the main transcription factor that mediates the activation of lipogenesis, and SREBP cleavage activating protein (SCAP) is required for the activation of SREBPs. Here, recent animal studies that suggest SCAP as a therapeutic target for hepatic steatosis and hypertriglyceridemia are discussed.

AB - Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance, obesity, and dyslipidemia. NAFLD encompasses a wide range of states from the simple accumulation of triglycerides in the hepatocytes to serious states accompanied by inflammation and fibrosis in the liver. De novo lipogenesis has been shown to be a significant factor in the development of hepatic steatosis in insulin-resistant states. Sterol regulatory element binding protein-1c (SREBP-1c) is the main transcription factor that mediates the activation of lipogenesis, and SREBP cleavage activating protein (SCAP) is required for the activation of SREBPs. Here, recent animal studies that suggest SCAP as a therapeutic target for hepatic steatosis and hypertriglyceridemia are discussed.

KW - Hypertriglyceridemia

KW - Insulin resistance

KW - Lipogenesis

KW - Non-alcoholic fatty liver disease

UR - http://www.scopus.com/inward/record.url?scp=85015973538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015973538&partnerID=8YFLogxK

U2 - 10.3803/EnM.2017.32.1.6

DO - 10.3803/EnM.2017.32.1.6

M3 - Review article

C2 - 28116873

AN - SCOPUS:85015973538

VL - 32

SP - 6

EP - 10

JO - Endocrinology and Metabolism

JF - Endocrinology and Metabolism

SN - 2093-596X

IS - 1

ER -